Acumen Pharmaceuticals develops experimental antibody treatments for Alzheimer's disease. It last closed at $0.19 on Nov 20, down 3.52% on the day. The next earnings report for ABOS is expected around Thu, Mar 25, 2027. For the quarter ended Sep 2026, ABOS reported EPS of -$0.35. Over its last 8 reports the stock moved an average of 5.1% the session after earnings. Over the last 12 months ABOS insiders bought $0 of stock on the open market and sold $626K, according to SEC Form 4 filings.
AI Auto Pilots
Is ABOS in one of our AI portfolios?
Five AI traders run real portfolios in the open, with every decision logged. Create a free account to see if they hold ABOS.
Close to close, the session after each report, adjusted for splits. Past moves are no guide to the next one.
StreetAlpha callBullish64%
OPTIONS
+2
DARK POOL
+1
HISTORY
0
TECHNICAL
+1
StreetAlpha's call on ABOSStart your 7 day free trial to see StreetAlpha's call before the report, with the options flow, dark pool, history and technical scores behind it.Sign up freeSign in
ABOS · as of the Nov 20 close · updated each morning
Downtrend, oversold
The stock is 240% below its 20 day and 741% below its 50 day average. It is 1158% below its 200 day average, so the longer trend is down. Momentum is weak (RSI 22), oversold. The nearest support is the Pivot at $0.18, and the nearest resistance the Pivot R1 at $0.20.
Short trendBearish
Long trendBearish
MomentumWeak
StretchOversold
VolatilityHigh, 67.9%/day
Key levels
$3.6052 week high+1794.7%
$2.35200 day average+1136.8%
$2.09100 day average+1000.0%
$1.5750 day average+726.3%
$0.6320 day average+231.6%
$0.23Swing high (Nov 17)+21.1%
$0.20Pivot R1+5.3%
$0.19Last close
$0.18Pivot−5.3%
$0.17Pivot S1−10.5%
$0.1652 week low−15.8%
Indicators
RSI (14)
21.56
Oversold below 30
Oversold
MACD
-0.44
Above its signal line
Bullish
Stochastic
17.5
Near the bottom of its range
Oversold
ADX (14)
44.1
Strong downtrend
Williams %R
-70.4
Oversold below −80, overbought above −20
Neutral
CCI (20)
-45.7
Oversold below −100, overbought above 100
Neutral
Rate of change
−16.6%
Change over 10 sessions
Bearish
ATR (14)
$0.13
Typical daily range, 67.9% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Below
MA 200Below
Downtrend, oversold
Short trendBearish
Long trendBearish
MomentumWeak
StretchOversold
VolatilityHigh, 247.5%/day
Key levels
$3.6052 week high+1794.7%
$2.35200 day average+1136.8%
$2.09100 day average+1000.0%
$1.5750 day average+726.3%
$0.6320 day average+231.6%
$0.23Swing high (Nov 17)+21.1%
$0.20Pivot R1+5.3%
$0.19Last close
$0.18Pivot−5.3%
$0.17Pivot S1−10.5%
$0.1652 week low−15.8%
Indicators
RSI (14)
28.69
Oversold below 30
Oversold
MACD
-0.53
Below its signal line
Bearish
Stochastic
0.9
Near the bottom of its range
Oversold
ADX (14)
26.1
Trending down
Williams %R
-99.2
Oversold below −80, overbought above −20
Oversold
CCI (20)
-178.1
Oversold below −100, overbought above 100
Oversold
Rate of change
−93.6%
Change over 10 sessions
Bearish
ATR (14)
$0.46
Typical daily range, 247.5% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Below
MA 200Below
What happened before, for ABOS
Signal name goes hereSince a recent date
9 times
+0.0%
Signal name goes hereSince a recent date
9 times
+0.0%
Signal name goes hereSince a recent date
9 times
+0.0%
What happened before
See how ABOS did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record. Free with an account.
November seasonalityHow ABOS usually does this month. See Seasonality
Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.
AI Day Trader
Watch Claude day trade the open, live.
Every session it trades SPY, QQQ, IWM and two daily stock picks, with each call logged before the move.
Whale options flow for ABOSHow many large options trades hit ABOS, the bullish and bearish split, and every trade with strike, premium and expiry are shown to AI Starter and AI Pro members.Sign up freeSign in
No whale options trades in ABOS in the last 90 days.
From SEC Form 4 filings by ABOS's officers, directors and 10% owners. Open market buys and sales only; option exercises, gifts, awards and tax withholding are left out. Not investment advice.
AI Auto Pilots
Paper trading
StreetAlpha runs autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether ABOS is in one of them and how their past ABOS trades turned out.
Acumen Pharmaceuticals is a biopharmaceutical company based in Newton, Massachusetts, that is developing treatments for Alzheimer's disease. Its lead candidate, sabirnetug, is an antibody designed to target soluble amyloid-beta oligomers, which the company believes play a central role in the disease. Sabirnetug is in a Phase 2 trial for people with mild cognitive impairment or mild dementia due to Alzheimer's. The company is also developing a brain-delivery platform with a partner and does not yet have a product on the market.